Comparing chemotherapy regimens before stem cell transplant for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing two different chemotherapy regimens (with one or two alkylating agents) before a stem cell transplant for people with acute myeloid leukemia or myelodysplastic syndrome. The goal is to find which conditioning treatment is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) in first complete remission, or you have myelodysplastic syndrome (MDS) with a certain amount of abnormal cells in the bone marrow (between 5% and 20%) at the time of transplant.
- You must have a stem cell donor who is either a matched sibling, a matched unrelated donor, or a half-matched related donor.
- No active central nervous system disease or spread of cancer outside the blood and bone marrow.
- No active infection that is not controlled, and no significant liver, kidney, lung, or heart problems.
- No uncontrolled mental health condition, and must not be HIV-positive.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger chemo and radiation plan before a stem cell transplant for people with myelodysplastic syndrome (a blood disorder) or acute myeloid leukemia (a blood cancer). The goal is to help the transplant work better and reduce the chance of the disease coming back.
This study compares two different drug combinations (BeFluBu and FluBuRux) used before a stem cell transplant from a half-matched (haploidentical) donor. The goal is to see which combination works better to prepare your body for the transplant and control your blood cancer.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a gentler chemotherapy regimen (fludarabine and treosulfan) before a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for older or frailer patients with acute myeloid leukemia.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This trial tests a combination of two chemotherapy drugs given before a stem cell transplant to help people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The goal is to improve the success of the transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.